Clinical Pharmacology of Balsalazide

Gian Maria Pacifici
Additional contact information
Gian Maria Pacifici: Professor of Pharmacology, Italy

Biomedical Journal of Scientific & Technical Research, 2024, vol. 58, issue 4, 50511-50516

Abstract: Balsalazide, a prodrug of 5-aminosalicylate, is used to treat ulcerative colitis. Balsalazide is metabolized by bacteria in the colon to release its therapeutically active moiety mesalazine. In adults, the oral dose of balsalazide is 6.75 grams and balsalazide is rapidly absorbed following oral administration.

Keywords: Journals on Medical Drug and Therapeutics; Journals on Emergency Medicine; Physical Medicine and Rehabilitation; Journals on Infectious Diseases Addiction Science and Clinical Pathology; Open Access Clinical and Medical Journal; Journals on Biomedical Science; List of Open Access Medical Journal; Journals on Biomedical Engineering; Open Access Medical Journal; Biomedical Science Articles; Journal of Scientific and Technical Research (search for similar items in EconPapers)
Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://biomedres.us/pdfs/BJSTR.MS.ID.009174.pdf (application/pdf)
https://biomedres.us/fulltexts/BJSTR.MS.ID.009174.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:abf:journl:v:58:y:2024:i:4:p:50511-50516

DOI: 10.26717/BJSTR.2024.58.009174

Access Statistics for this article

Biomedical Journal of Scientific & Technical Research is currently edited by Robert Thomas

More articles in Biomedical Journal of Scientific & Technical Research from Biomedical Research Network+, LLC
Bibliographic data for series maintained by Angela Roy ().